1.Izinkulungwane zamaRandi zezidakamizwa zaseNdiya ze-COVID-19 seziphelile?Qapha!
Muva nje, isihloko esimayelana "nezidakamizwa ezijwayelekile ze-COVID-19 zaseNdiya zathengiswa ngezinkulungwane zama-yuan ebhokisini" sivele ohlwini lokusesha oludumile lwe-microblog.Eminye imithi yathengwa egameni le-China News Network, futhi isitoko sase sithengisiwe, ngakho-ke kwakudingeka ukuthi uzibhukhe kusasele isonto.Odokotela bakhumbuza ukuthi izidakamizwa akufanele zithengwe ngemigudu engahlelekile.Ngaphezu kwalokho, amaqembu angeyona ingozi enkulu awadingi ukusebenzisa umuthi womlomo we-COVID-19.
Intengo yoqobo yebhokisi lezidakamizwa ingama-yuan angama-2300, futhi inani lokuthenga eNdiya lingamayuan ayi-1600.
"Manje ama-oda asebhukhwe ngokuphelele."Amanxusa amaningana aseNdiya athenga izidakamizwa atshele i-chinanews.com ukuthi izidakamizwa zabo ezijwayelekile ze-Pfizer COVID-19 oral Paxlovid sezithengisiwe muva nje.Uma kunesidingo, bangakhokha kuphela idiphozi kuqala, futhi izimpahla zingalethwa ngesonto ekuqaleni, noma ngenyanga ezayo kancane kakhulu.
Uma amagama athi “COVID-19 India”, “COVID-19 generic drugs” nokunye efakwa endaweni ye-e-commerce, abathengi bangathola ngokushesha ulwazi lwalaba benzeli bokuthenga, kodwa ngokuvamile badinga ukwengeza abangani be-WeChat, futhi bese wazisa imininingwane ethile yezimpahla kanye nezidingo zokuthenga.
Imithi ejwayelekile ye-Paxlovid ethengiswa yilawa ma-ejenti ihlanganisa i-Primovir epakishweni eluhlaza kanye ne-Paxista epakishweni eluhlaza okwesibhakabhaka.Eyokuqala ikhiqizwa i-Astrica, inkampani yaseNdiya, kanti eyakamuva ikhiqizwa i-Azista, inkampani engaphansi kwebhizinisi lezemithi laseNdiya iHetero.Njengamanje, i-Primovir enezinto ezipakishwayo eziluhlaza iyekile ukukhiqizwa, futhi yi-Paxista kuphela enamaphakethe aluhlaza esathengiswa.
Omunye umenzeli wethula ukuthi intengo yemeyili yasekhaya ingu-1600 yuan ibhokisi ngalinye, kanti eye-imeyili eqondile yaphesheya yayingu-1200 yuan ibhokisi ngalinye, ishibhile ngamayuan angama-400.Intengo yokuthenga ye-Paxlovid e-China ingu-2300 yuan ibhokisi ngalinye.
Le mithi ejwayelekile kunzima ukuyithenga esitokweni njengamanje.Ngokuvumelana nokuthengwa kwe-ejenti okungenhla, ukubhukha kwamukelekile, futhi imeyili eqondile yaseNdiya izofika e-China cishe ezinsukwini eziyi-15-20.Uphinde waphakamisa ukuthi umuntu ngamunye angathenga amabhokisi ama-2 kuphela.
Odokotela bayakhumbuza: Kunzima ukuhlukanisa iqiniso namanga.Hlala uqaphile
Eqinisweni, i-Paxlovid kade isetshenziswa ekwelapheni ukutheleleka nge-COVID-19 eChina, kodwa isetshenziswa kakhulu kwezinye izibhedlela eziqokiwe futhi idinga ukugunyazwa kwemiyalelo yodokotela.Akuzona zonke izibhedlela ezinomuthi.
Kubalulekile ukuqaphela ukuthi eminye imithi ejwayelekile ethengiswa ngekhomishini ingathengwa ngaphandle kokunikeza ngisho nencwadi kadokotela.Kulokhu, odokotela abangochwepheshe bakhumbuza wonke umuntu ukuba aqaphe.
“Njengodokotela abangochwepheshe asikhuthazi ukuthi kuthengwe izifanisi zakwamanye amazwe ngoba kunzima ukuhlukanisa okuyiqiniso nokungamanga.”UZhang Jiming, iphini likamqondisi weNational Infectious Diseases Medical Center kanye nodokotela omkhulu, uprofesa kanye nomphathi wesibhedlela saseHuashan esisebenzisana neFudan University, utshele abezindaba.com ukuthi ezinye zeziguli axoxisana nazo noma imindeni yazo ithenge okulingisa ngasese, futhi babekhathazekile ngokuthi bathenga izidakamizwa zomgunyathi.Uthe bekunzima ukuqinisekisa izinga lemithi ejwayelekile evela emthonjeni kanye nezimo zokugcinwa kwezidakamizwa uma uthenga imithi ejwayelekile kwamanye amazwe.
UZhang Jiming wethule ukuthi umuthi womlomo we-COVID-19 usetshenziselwa ikakhulukazi amaqembu asengozini enkulu ukuvikela izifo ezinzima, futhi ungasebenza kuphela uma usetshenziswa kusenesikhathi.Amaqembu angeyona ingozi enkulu akudingeki ajahe ukuthenga, futhi ukuxhashazwa kungase kubangele ukumelana nezidakamizwa.Akudingekile futhi ngokomtholampilo, ngoba iziguli eziningi azibonakali kahle noma zithambile, futhi isifo sinomkhawulo.
Utshele abezindaba.com ukuthi, mayelana nesimo saseShanghai, izibhedlela ezinkulu, izibhedlela eziqokiwe ze-COVID-19 nezinye izikhungo zezokwelapha ngokuvamile zinenani elithile lemithi elwa ne-COVID-19, esetshenziswa amaqembu asengozini enkulu ahlangabezana nezinkomba futhi utheleleke nge-COVID-19, ukuze kuvinjelwe izifo ezinzima futhi kwehliswe izinga lokufa.
Ngaphezu kwalokho, ngokwemibiko yabezindaba, abasebenzi bezomthetho bakhumbuza ukuthi izidakamizwa ezijwayelekile zase-India COVID-19 ezithengiswa ku-inthanethi azikakagunyazwa eChina.Ngaphansi koMthetho wamanje Wokuphathwa Kwezidakamizwa wase-People's Republic of China, nakuba izidakamizwa ezisohlwini lwamazwe aphesheya kodwa ezingakagunyazwa eShayina azisahlonzwa njengezidakamizwa zomgunyathi, abasebenzisa izidakamizwa basazobhekana nezijeziso zokuphatha ngokungenisa izidakamizwa ngokungemthetho.
2.U-Xinlitai uhambile!Iphethe izinhlobo ezimbili zezigidigidi ezi-1, izinhlobo eziyi-11 zemithi emisha ye-Class 1.
Muva nje, ipayipi le-Xinlitai R&D lenze inqubekelaphambili entsha.Kusetshenziswe amaphilisi omuthi omusha we-Class 1 SAL0133 ukuze asetshenziswe emtholampilo.Imiphumela yokuqala yokuhlaziywa kwezibalo itholwe ocwaningweni lomtholampilo lwe-Phase Ib lwe-PCSK9 antibody monoclonal.Kusukela ngo-2022, i-Xinlitai ifake isicelo se-IND/NDA semithi emisha engu-7, futhi ucwaningo nokuthuthuka kuthuthukiswe kancane kancane.Njengamanje, i-Xinlitai inezinhlobo ezimbili zezinga eliyizigidi eziyizinkulungwane ezingu-1, ezingu-22 zazo ezihloliwe (eziyi-8 zingezokuqala);Imithi emisha engu-21 ingaphansi kocwaningo, engu-6 yayo isesigabeni somtholampilo se-NDA noma iSigaba sesi-III, futhi umzila wokuqamba kabusha usungene esikhathini sokuthola imali.
Kuvela Imithi Yomlomo Ebanzi ye-COVID-19!I-Xinlitai Ingena Kusengi ye-COVID-19
Ngomhla zingama-20 kuZibandlela, u-Xinlitai wamemezela ukuthi ukusetshenziswa komtholampilo kwe-SAL0133, i-molecule encane yomuthi osungulwe ngokuzimela yinkampani, yamukelwe yi-State Food and Drug Administration.I-SAL0133 iyisivimbeli esinamandla, esibanzi esilwa noveli i-coronavirus 3CL protease (3CLpro) esungulwe ngokuzimela futhi yathuthukiswa inkampani enamalungelo azimele empahla yengqondo.Njengamanje, inkomba yomtholampilo okufanele yenziwe ukwelapha inyumoniya ye-coronavirus (COVID-19) yabantu abadala.
I-3CLpro idlala indima ebalulekile ekuphindaphindeni kwe-RNA ye-coronavirus yenoveli, ikakhulukazi esigabeni sokuqala sokuphindaphinda ngemva kokuba igciwane lingene kuseli eliphethe, livimbele umsebenzi we-3CLpro protease, engavimba ngempumelelo ukuphindaphinda kwegciwane futhi ifeze indima ye-anti novel coronavirus.
I-SAL0133 inendlela ecacile yokwenza, futhi inomphumela oqinile, obanzi wokulwa ne-COVID-19.Kulindeleke ukuthi ayidingi kuhlangana ne-CYP3A4 inhibitor ritonavir, futhi ingozi engaba khona yokusebenzisana nezidakamizwa iphansi;Kulindeleke ukuthi kuzuzwe ukusetshenziswa kwesidakamizwa esisodwa emtholampilo kanye ngosuku futhi kuthuthukiswe ukuthobela imithi yesiguli.Uma ingathuthukiswa ngempumelelo futhi ivunyelwe ukumakethwa, izohlinzeka iziguli ukukhetha kwemithi emisha ukuhlangabezana nezidingo zomtholampilo ezingahlangatshezwana nazo.
Ucwaningo nokuthuthukiswa kwezidakamizwa ze-3CL ezihlosiwe ze-anti-COVID-19 zomlomo ze-molecule encane kudonse ukunaka okubanzi.Njengamanje, i-Pfizer's Paxlovid kuphela evunyelwe ukumakethwa emhlabeni.Bangaphezu kwe-10 amabhizinisi asekhaya emithi kanye nezikhungo zocwaningo lwesayensi abenze ucwaningo kanye nokuthuthukiswa kwezidakamizwa eziqondiswe ku-3CL ezibhekiswe ku-COVID-19, okuhlanganisa i-FB2001 ye-Frontier Biology, i-VV993 ye-Junshi Biology/Wangshan Wangshui, i-SIM0417 ye-Pioneer Pharmaceutical, i-RAY1216 ye-Pharmaceutical tablet ye-Zhonggutical I-GST-HG171 yase-Guangshengtang, njll.
Njengoba kunezinhlobo ezi-2 ezinkulu zebhiliyoni engu-1 esandleni, izidakamizwa ezintsha ezi-7 kulo nyaka zamukela inqubekelaphambili entsha
Ngasekupheleni kuka-2022, njengommeleli ojwayelekile woguquko lwe-R&D embonini yezemithi, i-Xinlitai ithole ngempumelelo eyakhe indlela yokuthuthukisa ubuhlakani ngaphansi kwengcindezi nokulungiswa.
Ezingxenyeni ezintathu zokuqala zika-2022, imali engenayo yenkampani ibingama-yuan ayizigidi eziyizinkulungwane ezingama-2.548, nokukhula konyaka ngo-16.5%, kanti inzuzo yayo yonke ibe ngama-yuan ayizigidi ezingama-539, nokukhula konyaka ngonyaka ngama-37.64%.Ukusebenza kahle kwabeka isisekelo esiqinile sentuthuko eyalandela.Inkampani ilindele ukuthi ngo-2022, i-Taijia (amaphilisi e-clopidogrel bisulfate) izozuza cishe ama-yuan ayizigidi eziyizinkulungwane ezingu-1, kanti i-Sinritan (amaphilisi e-alisartan) izozuza cishe ama-yuan ayizigidi ezingu-900 kuya ku-yuan webhiliyoni elingu-1.Le nkampani inezinhlobo ezingama-22, eziyisi-8 kuzo ingeyokuqala eChina.
Ngo-2019, uhlobo oluyinhloko lwe-Xinlitai, e-Taijia, lwalahlekelwa isicelo salo ekuthengeni okumaphakathi kwe-4+7, okuphoqe u-Xinlitai ukuthi enze izinguquko.Embikweni wonyaka ka-2019, u-Xinlitai umemezele ukuthi "ipayipi locwaningo lizolungiswa ngendlela esezingeni eliphezulu, futhi amaphrojekthi e-anti-tumor biological analog kanye nama-antibiotics kwezinye izigaba zomtholampilo azoqedwa".Ngo-2020, ukuze kuqhutshekwe nokuthuthukisa ipayipi ngaphansi kocwaningo futhi kugxilwe ku-R&D kanye nokukhuthazwa kwemikhiqizo emisha, i-Xinlitai yadlulisela amalungelo afanelekile nezintshisekelo ze-dapoxetine hydrochloride, i-erlotinib hydrochloride, i-rivasaban namanye amaphrojekthi, futhi yathola imali yokudlulisa.
Ngemuva kokulungiswa okuthile, okwamanje, ipayipi lezidakamizwa ezijwayelekile lase-Xinritai linesicelo sokumaketha se-Class 4 kuphela sokulingisa amaphilisi e-sodium ye-Sakubatrovalsartan esibuyekezwayo, kanye nesicelo sokwengeza sokuhlolwa okungaguquguquki kwe-cefuroxime sodium yokujova kanye ne-cefotaxime sodium yomjovo ngaphansi kokubuyekezwa.Kuhle ukusho ukuthi kusukela ngoJulayi 2019, i-Xinlitai ayikaze ifake isicelo semithi emisha emisha iminyaka engaphezu kwemi-3, futhi igxile ekusungulweni nasekucwaningeni.
Kusukela ngo-2022, i-Xinlitai yenze inqubekelaphambili eqhubekayo ocwaningweni nasekuthuthukisweni kwezidakamizwa ezintsha.Ngomhla zi-4 kuJanuwari, 2022, ukusetshenziswa okufakwe kuhlu kwamaphilisi e-CINRITAI e-HIF-PHI inhibitor Enasitar kwenziwa yi-CDE;Ngokulandelayo, iNkampani yathumela izicelo zomtholampilo zemithi emihlanu emisha ye-Class 1, okungukuthi, i-recombinant human neuromodulin-1 anti HER3 antibody fusion protein injection, amaphilisi e-SAL0112, umjovo we-SAL008, amaphilisi e-SAL0119 kanye namaphilisi e-SAL0133;Ngomhla zi-3 kuNovemba, ikilasi elisha le-2.3 lenze ngcono isidakamizwa i-alisartan namaphilisi e-amlodipine e-SINRITAI athumele isicelo sokufakwa kuhlu, okulindeleke ukuthi sakhe ukusebenzisana kwamasu nesigaba sohlu 1.1 somuthi we-antihypertensive SINRITAI.
I-JinDun Medicalinokubambisana kocwaningo lwesayensi yesikhathi eside kanye nokuxhunyelelwa kwezobuchwepheshe namanyuvesi aseShayina.Ngezinsiza zezokwelapha ezicebile ze-Jiangsu, inobudlelwano besikhathi eside bokuhwebelana ne-India, i-Southeast Asia, iNingizimu Korea, iJapan nezinye izimakethe.Iphinde inikeze izinsizakalo zemakethe nezokuthengisa kuyo yonke inqubo kusukela ku-API yomkhiqizo omaphakathi kuya oqediwe.Sebenzisa izinsiza eziqoqiwe ze-Yangshi Chemical kukhemistri ye-fluorine ukuze unikeze izinsizakalo ezikhethekile zokwenza amakhemikhali ngokwezifiso kozakwethu.Nikeza inqubo emisha kanye nezinsizakalo zocwaningo lokungcola ukuze uqondise amakhasimende.
I-JinDun Medical iphikelela ekudaleni iqembu elinamaphupho, lenze imikhiqizo enesithunzi, ecophelelayo, eqinile, futhi iphume konke ukuze ibe uzakwethu othembekile kanye nomngane wamakhasimende! professionalukukhiqizwa kwemithi ngokwezifiso(i-CMO) kanye nabahlinzeki besevisi be-R&D bezemithi kanye nokukhiqiza (CDMO).UJindun uzokuphelezela ukuyochitha i-COVID-19.
Isikhathi sokuthumela: Jan-28-2023